ライフサイエンスコーパス: isolated systolic hypertension

1 et for age-associated vascular stiffness and isolated systolic hypertension.

2 in older adults (aged 60 years or more) with isolated systolic hypertension.

3 in kidney function among older persons with isolated systolic hypertension.

4 ebo-controlled trials has been beneficial in isolated systolic hypertension.

5 lity, which occurs with aging, diabetes, and isolated systolic hypertension.

6 factor and extend the findings to borderline isolated systolic hypertension.

7 rs are important in older men and women with isolated systolic hypertension.

8 io = 1.18, 95% CI: 1.10, 1.26), but not with isolated systolic hypertension.

9 HEP) of patients aged 60 years or older with isolated systolic hypertension.

10 8 (1.69 to 1.87) and 1.68 (1.58 to 1.78) for isolated systolic hypertension, 1.59 (1.43 to 1.76) and

11 tients with diabetes, -8.6 +/- 18.7 mm Hg in isolated systolic hypertension, -10.1 +/- 20.3 mm Hg in

12 Treatment of isolated systolic hypertension and combined systolic and

13 r to atenolol for treatment of patients with isolated systolic hypertension and ECG-LVH.

14 Hypertension as well as borderline isolated systolic hypertension are associated with eleva

15 herapy is effective in elderly patients with isolated systolic hypertension, attention has been focus

16 ormotensive individuals and individuals with isolated systolic hypertension but not in individuals wi

17 Heart failure is often preceded by isolated systolic hypertension, but the effectiveness of

18 ssure at the time of scanning are small, but isolated systolic hypertension could cause increases in

19 equences on cardiovascular health, including isolated systolic hypertension, excessive penetration of

20 stolic pressure that separates patients with isolated systolic hypertension from those with essential

21 The association between homocysteine and isolated systolic hypertension in older adults was evalu

22 ly Program (SHEP) demonstrated that treating isolated systolic hypertension in older patients decreas

23 homocysteine may be related to the cause of isolated systolic hypertension in some individuals.

24 nal studies confirm the benefits of treating isolated systolic hypertension in the elderly.

25 In contrast to the wealth of data on isolated systolic hypertension involving the systemic ci

26 Isolated systolic hypertension is the dominant variety.

27 Isolated systolic hypertension is the predominant form o

28 ave systolic/diastolic hypertension, whereas isolated systolic hypertension (ISH) is common among per

29 a common problem among elderly patients with isolated systolic hypertension (ISH), but the effect of

30 Isolated systolic hypertension (ISH), defined as systoli

31 the risk of stroke in elderly patients with isolated systolic hypertension (ISH).

32 whether definite hypertension and borderline isolated systolic hypertension predict subsequent cardio

33 isk of myocardial infarction, and borderline isolated systolic hypertension predicts a possible but m

34 herapy, especially in older patients in whom isolated systolic hypertension predominates, controlling

35 rtension (SBP >or=140 and DBP >or=90 mm Hg), isolated systolic hypertension (SBP >or=140 and DBP <90

36 Patients with isolated systolic hypertension should be treated, but ma

37 In older persons with isolated systolic hypertension, stepped-care treatment b

38 Isolated systolic hypertension was associated with incre

39 Borderline isolated systolic hypertension was associated with signi

40 Hypertension and borderline isolated systolic hypertension were associated with sign

41 In the SHEP trial, treatment of isolated systolic hypertension with chlorthalidone stepp

42 Adults aged >/=60 years (older) have mainly isolated systolic hypertension, with major trials attain

43 rs versus age <65 years, with versus without isolated systolic hypertension, with versus without atri